The efficacy and safety of Chaihu guizhi ganjiang tang for type 2 diabetes mellitus: a systematic review and meta-analysis
Abstract
Background: The pathological mechanisms of type 2 diabetes mellitus (T2DM) are complex and necessitate multi-target intervention strategies. Chaihu Guizhi Ganjiang Tang (CHGZGJT), a classical formula derived from the ancient canonical text Shanghan Lun (Treatise on Cold Damage Diseases), has been reported to improve glucose and lipid metabolism as well as islet function in patients with T2DM. However, a quantitative evidence-based evaluation is currently lacking. This study aimed to systematically evaluate the overall efficacy and safety of CHGZGJT.
Methods: This study was registered on the PROSPERO platform. Eight Chinese and English databases and two clinical trial registries were systematically searched, and 12 clinical controlled trials involving a total of 883 patients were ultimately included. Meta-analysis were performed using R software to assess efficacy and safety.
Results: The meta-analysis suggested that CHGZGJT combined with conventional treatment significantly reduced glycated hemoglobin (HbA1c, MD = -0.69%), fasting plasma glucose (FPG, MD = -0.86 mmol/L), and 2-h postprandial glucose (2hPG, MD = -0.74 mmol/L) in patients with T2DM. At the mechanistic level, this regimen significantly decreased fasting insulin (FINS, MD = -2.08 µIU/mL) and the homeostasis model assessment of insulin resistance (HOMA-IR, MD = -0.79), improved islet β-cell function (HOMA-β, MD = 5.13), and lowered total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels,…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 883 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.